7 Jun, 2021

FDA approval of debated Alzheimer’s drug is tremendous for society: Alzheon CEO

alzheon2024-08-05T18:57:02-04:00June 7th, 2021|Tags: BNN|

Read More

4 Jun, 2021

Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease

alzheon2024-08-26T10:57:03-04:00June 4th, 2021|Tags: Press Release Tag|

Read More

6 May, 2021

Biotech Startup Alzheon Strikes Deal to Develop Alzheimer’s Test

alzheon2024-07-29T15:34:39-04:00May 6th, 2021|Tags: WSJ|

Read More

4 May, 2021

Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain

alzheon2024-08-26T11:01:41-04:00May 4th, 2021|Tags: Press Release Tag|

Read More

9 Mar, 2021

New Drug Approval Could Be on Horizon for Alzheimer’s after 17-Year Drought

alzheon2024-07-29T15:57:00-04:00March 9th, 2021|Tags: BioSpace.com|

Read More

9 Mar, 2021

Alzheon to Present at H.C. Wainwright Global Life Sciences Conference

alzheon2024-08-26T11:02:06-04:00March 9th, 2021|Tags: Press Release Tag|

Read More

24 Feb, 2021

Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit

alzheon2024-08-05T19:43:03-04:00February 24th, 2021|

Read More

9 Dec, 2020

Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease

alzheon2024-08-26T11:00:13-04:00December 9th, 2020|Tags: Press Release Tag|

Read More

4 Dec, 2020

APOE ε4/ε4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline

alzheon2024-08-09T11:39:48-04:00December 4th, 2020|

Read More

1 Dec, 2020

Potential for an Alzheimer’s Treatment Appears to Be Closer Than Ever

alzheon2020-12-07T09:44:16-05:00December 1st, 2020|Tags: BioSpace.com|

Read More